Document is current

Article History

Received: 28 December 2021

Accepted: 5 April 2022

First Online: 30 April 2022

Declarations

:

: AS was an honorary speaker for TAD Pharma and Roche and a member of Roche advisory boards. AH is co-editor of the German (DGPPN) schizophrenia treatment guidelines and first author of the WFSBP schizophrenia treatment guidelines; he has been on the advisory boards and has received speaker fees from Janssen-Cilag, Lundbeck, and Otsuka. PF is a co-editor of the German (DGPPN) schizophrenia treatment guidelines and a co-author of the WFSBP schizophrenia treatment guidelines; he is on the advisory boards and receives speaker fees from Janssen, Lundbeck, Otsuka, Servier, and Richter. AML has received consultant fees from Boehringer Ingelheim, Elsevier, Brainsway, Lundbeck Int. Neuroscience Foundation, Lundbeck A/S, Sumitomo Dainippon Pharma Co., Academic Medical Center of the University of Amsterdam, Synapsis Foundation-Alzheimer Research Switzerland, IBS Center for Synaptic Brain Dysfunction, Blueprint Partnership, University of Cambridge, Dt. Zentrum für Neurodegenerative Erkrankungen, Zürich University, Brain Mind Institute, L.E.K. Consulting, ICARE Schizophrenia, Science Advances, Fondation FondaMental, v Behring Röntgen Stiftung, The Wolfson Foundation, and Sage Therapeutics; Additionally, he has received speaker fees from Lundbeck International Foundation, Paul-Martini-Stiftung, Lilly Deutschland, Atheneum, Fama Public Relations, Institut d'investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Janssen-Cilag, Hertie Stiftung, Bodelschwingh-Klinik, Pfizer, Atheneum, University of Freiburg, Schizophrenia Academy, Hong Kong Society of Biological Psychiatry, Fama Public Relations, Spanish Society of Psychiatry, Italian Society of Biological Psychiatry, Reunions I Ciencia S.L., and Brain Center Rudolf Magnus UMC Utrecht as well as the Prix Roger de Spoelberch grant and the CINP Lilly Neuroscience Clinical Research Award 2016. BEW’s spouse is an employee of Siemens Healthineers. IM, LR, DK, TK, BP, DH, ES, SM, VS, MC, EW, LL, AR, ML, KV, IP, BM, JP and SS report no conflicts of interest.

: Before participation subjects provided written informed consent. All study procedures complied with the Declaration of Helsinki and were approved by the local ethic committee (project nr. 706-15, date 18.05.2016). The study was registered on the U.S. Department of Health`s website, a database of clinical trials conducted worldwide (NCT number: NCT03466112), and on the German Clinical Trials Register (DRKS-ID: DRKS00009804).